121 related articles for article (PubMed ID: 25466947)
1. Re:Mark K. Buyyounouski. Radiobiological modeling and the study of hypofractionated radiotherapy for prostate cancer. Eur Urol 2014;66:1031-2.
Fiorino C; Briganti A; Cozzarini C
Eur Urol; 2015 Mar; 67(3):e56-7. PubMed ID: 25466947
[No Abstract] [Full Text] [Related]
2. Radiobiological modeling and the study of hypofractionated radiotherapy for prostate cancer.
Buyyounouski MK
Eur Urol; 2014 Dec; 66(6):1031-2. PubMed ID: 25130566
[No Abstract] [Full Text] [Related]
3. Re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur urol 2014;66:1024-30.
De Bari B; Alongi F; Arcangeli S
Eur Urol; 2014 Dec; 66(6):e111-2. PubMed ID: 25190611
[No Abstract] [Full Text] [Related]
4. Reply to Berardino De Bari, Filippo Alongi, Stefano Arcangeli's letter to the editor re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur urol 2014;66:1024-30.
Cozzarini C; Fiorino C; Briganti A; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):e113-4. PubMed ID: 25199719
[No Abstract] [Full Text] [Related]
5. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
[TBL] [Abstract][Full Text] [Related]
6. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
7. Relationships between bladder dose-volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer.
Carillo V; Cozzarini C; Rancati T; Avuzzi B; Botti A; Borca VC; Cattari G; Civardi F; Esposti CD; Franco P; Girelli G; Maggio A; Muraglia A; Palombarini M; Pierelli A; Pignoli E; Vavassori V; Zeverino M; Valdagni R; Fiorino C
Radiother Oncol; 2014 Apr; 111(1):100-5. PubMed ID: 24631144
[TBL] [Abstract][Full Text] [Related]
8. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
[TBL] [Abstract][Full Text] [Related]
9. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
10. Predictors of acute urinary symptom flare following stereotactic body radiation therapy (SBRT) in the definitive treatment of localized prostate cancer.
Repka MC; Kole TP; Lee J; Wu B; Lei S; Yung T; Collins BT; Suy S; Dritschilo A; Lynch JH; Collins SP
Acta Oncol; 2017 Aug; 56(8):1136-1138. PubMed ID: 28270015
[No Abstract] [Full Text] [Related]
11. Urologic Complications Following Pelvic Radiotherapy.
Lobo N; Kulkarni M; Hughes S; Nair R; Khan MS; Thurairaja R
Urology; 2018 Dec; 122():1-9. PubMed ID: 30036617
[TBL] [Abstract][Full Text] [Related]
12. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy.
Marks LB; Carroll PR; Dugan TC; Anscher MS
Int J Radiat Oncol Biol Phys; 1995 Mar; 31(5):1257-80. PubMed ID: 7713787
[TBL] [Abstract][Full Text] [Related]
13. Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience.
Fonteyne V; Sadeghi S; Ost P; Vanpachtenbeke F; Vuye P; Lumen N; De Meerleer G
Acta Oncol; 2015 Jun; 54(6):854-61. PubMed ID: 25387271
[TBL] [Abstract][Full Text] [Related]
14. Minimizing the number of implantation needles for prostate (125)I brachytherapy: an investigation of possibilities and implications.
Steggerda MJ; van der Poel HG; Moonen LM
Brachytherapy; 2010; 9(4):319-27. PubMed ID: 20691644
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer: biological dose considerations and constraints in tele- and brachytherapy.
Dörr W; Jaal J; Zips D
Strahlenther Onkol; 2007 Dec; 183 Spec No 2():14-5. PubMed ID: 18166999
[No Abstract] [Full Text] [Related]
16. [Normal tissue radiation toxicity in radiotherapy of localized prostatic cancer].
Bakken AM; Ogreid P; Iversen J; Langberg CW
Tidsskr Nor Laegeforen; 1999 May; 119(14):2017-21. PubMed ID: 10394276
[TBL] [Abstract][Full Text] [Related]
17. Comparison of different fractionation schedules toward a single fraction in high-dose-rate brachytherapy as monotherapy for low-risk prostate cancer using 3-dimensional radiobiological models.
Mavroidis P; Milickovic N; Cruz WF; Tselis N; Karabis A; Stathakis S; Papanikolaou N; Zamboglou N; Baltas D
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):216-23. PubMed ID: 24331667
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of late side-effects of conformal and conventional radiotherapy in locally limited prostatic carcinoma. A prospective randomized study].
Feldmann HJ
Strahlenther Onkol; 1999 Jul; 175(7):350-1. PubMed ID: 10433000
[No Abstract] [Full Text] [Related]
19. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
20. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
